# CJC-1295 Ipamorelin as a Growth Hormone Secretagogue

> CJC-1295 Ipamorelin as a Growth Hormone Secretagogue: how a long-acting GHRH analogue and a selective GHRP combine to coax the pituitary's own growth hormone, with the class safety record cited.

Not growth hormone itself, but the two signals that ask the body to make its own — the cleanest expression of the secretagogue idea.

## Start here

CJC-1295 Ipamorelin as a growth hormone secretagogue means this: neither peptide *is* growth hormone. Each is a *secretagogue* — a signal that asks the body's own pituitary gland to release more of its own GH, rather than injecting GH from outside. A growth hormone secretagogue works with the body's natural pulse instead of overriding it, which is the design idea behind this whole class.

The pairing is the secretagogue idea in its tidiest form: two different natural 'release' signals — GHRH and ghrelin — copied and pushed together. That is why the combination is so often discussed under the secretagogue heading. The class is generally well tolerated in the short term, but it is not without a metabolic catch, and none of it is FDA-approved. This page explains how the two arms work as secretagogues, why that differs from taking GH, and what the class safety record actually says.

## What a growth hormone secretagogue is

A growth hormone secretagogue is any compound that triggers the pituitary to secrete its own growth hormone. The body has two natural accelerators for this: GHRH, made in the hypothalamus, and ghrelin, the hormone better known for hunger, which also drives GH through its own receptor. A secretagogue mimics one of those. Crucially, this preserves the body's feedback loop — IGF-1 still rises and still feeds back to restrain the axis — which is the headline distinction from injecting exogenous GH, where no such pulsatile, self-limiting pattern exists. Ipamorelin earned the specific title of the *first selective* growth hormone secretagogue: it released GH without raising ACTH or cortisol even at more than 200 times the GH-releasing dose [2].

## Two secretagogues, two pathways

The combination pairs the two secretagogue classes. CJC-1295 is the GHRH-analogue arm: it binds the GHRH receptor and works through cAMP, and its DAC form holds that signal for days by binding albumin [1][5]. Ipamorelin is the GHRP arm: it binds the ghrelin receptor (GHS-R1a) and works through calcium, delivering a short, clean pulse [2]. Because the two secretagogue pathways are independent, stimulating both at once releases GH synergistically — Bowers established the human synergy in 1990 [3], and Cunha and Mayo found the cloned receptors together produced about twice the cAMP of GHRH alone in 2002 [4]. One secretagogue holds; the other strikes; together they ask for a bigger pulse than either could alone.

## The secretagogue safety record

The class safety picture is the honest centre of any growth hormone secretagogue discussion. The best synthesis — a review of GH secretagogues — found them generally well tolerated, with the chief safety concern being increased blood glucose from decreased insulin sensitivity, and explicitly noted that long-term data on cancer incidence and mortality are still needed [6]. That is the secretagogue trade in one sentence: a generally clean short-term profile, a predictable glucose signal because GH opposes insulin, and unresolved long-term questions because the long studies have not been done. Layer on that neither CJC-1295 nor ipamorelin is approved by any regulator, the fixed pair has never been trialled, and both are WADA-prohibited under Section S2, and the full secretagogue context is on the table.

## Why the secretagogue framing matters here

Reading CJC-1295 Ipamorelin as a growth hormone secretagogue keeps the claims honest. It explains why the literature leads with GH and IGF-1 *levels* — those are what a secretagogue directly changes — rather than with body-composition outcomes, which are downstream and, for this fixed pair, unmeasured. It explains why the sleep angle is mechanistically reasonable: the ghrelin secretagogue arm is tied to slow-wave sleep [8], and GH itself crests in deep sleep. And it explains the safety shape: the risks are GH-axis risks — glucose, fluid, the theoretical IGF-1/proliferation concern [6][1] — because a secretagogue's whole job is to raise the GH the body makes. The framing is not decoration; it is the most accurate lens on what these two peptides do and do not do.

---

A nightfall reading of the CJC-1295 and ipamorelin literature — the aurora is wonder, the steel is rigor, and nothing here is a clinic, a prescription, or a thing for sale.